DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/kp58fb/waldenstrms_macr) has announced the addition of GlobalData's new report "Waldenstrm's Macroglobulinemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019" to their offering.
GlobalData, the industry analysis specialist, has released its new report, Waldenstrm's Macroglobulinemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Waldenstrm's macroglobulinemia therapeutics market. The report identifies the key trends shaping and driving the global Waldenstrm's macroglobulinemia therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Waldenstrm's macroglobulinemia therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
The Waldenstrm's Macroglobulinemia Therapeutics Market is Forecast to Decline Until 2019
GlobalData estimated the global Waldenstrm's macroglobulinemia therapeutics market to be worth $201.4m in 2011. From 2006 - 2011, the market grew at a Compound Annual Growth Rate (CAGR) of 4.3%, from $163.3m in 2006 to $201.4m in 2011. However, the Waldenstrm's macroglobulinemia therapeutics market is forecast to decline at a CAGR of 2.4% for the next eight years to reach $165.6m by 2019. Key factors likely to impact the market in the future include:
Lack of molecules in Phase III of development in the pipeline.
The patents of currently used off-label therapeutic agents such as rituximab are set to expire in 2015 in the US and 2014 in the EU. Similarly, bortezomib will lose its patent in 2017 in the US and 2019 in the EU and thalidomide will lose its patent in 2019 in the EU.
Companies Mentioned
- AEterna Zentaris Inc
- Allos Therapeutics, Inc
- ELI Lilly
- Genmab A
- GlaxoSmithKline
- Novartis
For more information visit http://www.researchandmarkets.com/research/kp58fb/waldenstrms_macr
Source: GlobalData